David K Ahern, PhD, (Abacus Chief Science Officer) Stephen J. Kogut, PhD, MBA, RPh and Jennifer Kellogg, MPH, (Healthy Weight Program Manager) have penned and article comparing the launch of Statin medications in the mid 1990s and the use of tobacco cessation to ultimately control cholesterol and reduce the risk of heart attacks, strokes and cardiovascular disease to the wave of GLP-1 anti-obesity medications and the need to have behavioral support services as a core part of an obesity intervention for self-funded health plans.
The article was published in Healthcare Business Today.
David K Ahern, PhD, and Stephen J. Kogut, PhD, MBA, RPh will be presenting on the topic of GLP-1s at the SALGBA (State and Local Government Business Association on May 5th, 2025 along with Dana Kruse, PharmD and Jill Gallant-Shaw, LIA
